Pharmacyte Biotech Inc (OTCMKTS:PMCB) is an emerging potential competitor to Ely Lilly (LLY) and its chemotherapy drug, gemcitabine. The stock has certainly had its ups and downs as the company battles for legitimacy with its alternative, which is to use its advanced, inoperable pancreatic cancer therapy, “which consists of the company’s signature live-cell encapsulation technology, Cell-in-a-Box, plus low doses of the FDA-approved chemotherapy drug ifosfamide, in its upcoming clinical trial where it will go head to head with gemcitabine in order to address an unmet medical need.”
In recent action, we’ve witnessed 6% during the past month in terms of shareholder gains in the name. The situation may be worth watching. PMCB is a stock who’s past is littered with sudden rips. Moreover, the name has witnessed a pop in interest, as transaction volume levels have recently pushed 37% over what the stock has registered over the longer term.
Pharmacyte Biotech Inc (OTCMKTS:PMCB) frames itself as a clinical stage biotechnology company that focuses on developing and commercializing treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology, known as Cell-in-a-Box. Its Cell-in-a-Box technology would be used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, and diabetes.
The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer.
It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and examining the benefits of the Cell-in-a-Box technology to develop therapies for cancer-based upon the constituents of the Cannabis plant.
The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Silver Spring, Maryland.
According to company materials, “PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide comes in contact with the encapsulated cells they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no side effects.”
Find out when PMCB stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
The company has been one for frequent road shows and engagements as it seeks to get its message out in what is something of a battle for hearts and minds in the space.
The most recent version of this process is the company’s announcement that its senior management team will attend the 53rd annual meeting of the American Society of Clinical Oncology (ASCO) to be held June 2-6, 2017, at McCormick Place in Chicago. The theme of this year’s meeting is “Making a Difference in Cancer Care with You.”
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, commented, “This year’s annual meeting of ASCO will be our most important as we work towards enrolling the first patient in our planned clinical trial in locally advanced pancreas cancer (LAPC). During this multi-day event, we will be hosting a special meeting of leading clinical oncologists who have expressed interest in participating in our clinical trial. This special meeting is designed to: (i) provide an update on the progress PharmaCyte has made this past year in getting ready for the trial; (ii) provide a timeline for filing the IND and for enrolling the first patient; (iii) make introductions of and allow for comments by key members of PharmaCyte’s Clinical Management Team (Dr. Manuel Hidalgo, Dr. Matthias Löhr, Translational Drug Development (TD2) and Imaging Endpoints, the two major CROs who will be conducting the trial for us); and (iv) gain a commitment from the oncologists and their respective cancer centers to participate in our exciting study.”
At this time, carrying a capital value in the market of $61.2M, PMCB has a bankroll ($2.5M) of cash on the books, which stands against virtually no total current liabilities. The company is pre-revenue at this point. This is an exciting story, and we look forward to a follow-up chapter as events transpire. For continuing coverage on shares of $PMCB stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!